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Abstract
Purpose—Poor body composition metrics (BCM) are associated with inferior cancer outcomes; 
however, in early breast cancer (EBC) there is a paucity of evidence regarding BCM’s impact on 
toxicities. This study investigates associations between BCM and treatment-related toxicity in 
EBC patients receiving anthracyclines-taxane based chemotherapy.
Experimental Design—Pretreatment computerized tomography (CT) images were evaluated 
for skeletal muscle area (SMA), density (SMD), and fat tissue at the 3rd lumbar vertebrae. Skeletal 
muscle index (SMI) (SMA/height2) and skeletal muscle gauge (SMG=SMI x SMD) were also 
calculated. Relative risks (RR) are reported for associations between body composition measures 
and toxicity outcomes, after adjustment for age and body surface area (BSA).
Results—BCM were calculated for 151 patients with EBC (median age 49, range 23 to 75). Fifty 
patients (33%) developed grade 3 or 4 toxicity, which was significantly higher in those with low 
SMI (RR=1.29, p=0.002), low SMG (RR=1.09, p=0.01), and low LBM (RR=1.48, p=.002). ROC 
analysis showed the SMG measure to be the best predictor of grade 3 and 4 toxicity. Dividing 
SMG into tertiles showed toxicity rates of 46%, and 22% for lowest versus highest tertile, 
respectively (p=0.005). After adjusting for age and BSA, low SMG (<1475 units) was significantly 
associated with hematological (RR=2.12, p=0.02), gastrointestinal grade 3–4 toxicities (RR=6.49, 
p=0.02), and hospitalizations (RR=1.91, p=0.05).
Conclusions—Poor BCM are significantly associated with increased treatment-related 
toxicities. Further studies are needed to investigate how these metrics can be used to more 
precisely dose chemotherapy to reduce treatment related toxicity while maintaining efficacy.
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Introduction
Breast cancer (BC) is the most common cancer diagnosis and the leading cause of cancer 
death among females worldwide(1). In the US in 2016, there will be an estimated 246,660 
new cases of BC(2). The overall survival from breast cancer in the US is 89.5% for all 
stages(3). The treatment of early stage BC (stage I–III) consists primarily of local therapy 
including surgery, with or without radiation, and systematic therapy such as endocrine, 
biological treatment (i.e. Trastuzumab) and/or chemotherapy. Chemotherapy is an essential 
component of treatment for early BC, especially in hormone receptor (HR) positive large/
node positive tumors or human epidermal growth factor receptor 2 (HER2) positive and HR/
HER2 negative tumors (“triple negative”). Chemotherapy toxicity is a major issue; among 
early BC patients who undergo chemotherapy, up to 20% can experience non-hematologic 
and 39% hematologic toxicity(4). Of note, hospitalization due to toxicity is common with 
adjuvant chemotherapy and ranges from 6–24% in the adjuvant setting(5). Toxicity 
prediction in individual patients remains a major challenge in BC care(6). However, with the 
established use of granulocyte-colony stimulating factor (g-CSF and related agents), the 
incidence of neutropenia has decreased substantially(7).
Sarcopenia (age-related muscle loss), myopenia (low muscle mass regardless of age) (8), 
and other body composition measures have received increased attention as a focus of 
research in oncology using widely available computed tomographic (CT) imaging(9). 
Sarcopenia is a common finding in patients with cancer. In a recent meta-analysis, 19–74% 
of patients with solid tumors were found to be sarcopenic, and the presence of sarcopenia 
was correlated with poor overall survival (HR=1.44, p<0.001) in both metastatic and non-
metastatic cohorts(9). However, in breast cancer there is a paucity of data on the potential 
effect of sarcopenia and other body composition measures on treatment-related toxicities. 
Wong et al examined the association between body composition and toxicity of 
anthracyclines and docetaxel used without growth factors in Asian patients with early BC 
(n=84) and found that increased visceral fat significantly correlated with grade 4 leukopenia 
(p=0.014) and that low muscle volume trended (n=15, p=0.051) towards an association with 
grade 3 and 4 leukopenia and neutropenia(10). Skeletal Muscle Density (SMD) can also be 
obtained from routine CT imaging by indirectly measuring intramuscular lipid content. Low 
SMD as measured by mean Hounsfield Units (HU), known as myosteatosis, indicates poor 
muscle ‘quality’ and has been associated with impaired survival (11, 12). Sarcopenic obesity 
is another marker for worse outcomes in cancer patients (12). While dosing is usually based 
on weight and height measures (body surface area (BSA)), there is evidence that 
pharmacokinetics and drug toxicities are more related to lean body mass (LBM) but to date, 
muscle measures have not been incorporated into routine chemotherapy dosing(13–16). As 
both muscle quantity (skeletal muscle index (SMI)) and quality (skeletal muscle density 
(SMD)) are significantly and independently associated with cancer outcomes, testing a 
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mathematical combination of both has been proposed. Weinberg et al were the first to 
generate the skeletal muscle gauge (SMG) by multiplying SMI times SMD as an alternative 
measure that showed higher correlation with aging than either SMD or SMI alone(17) and 
we have used this metric as part of our current analysis.
These findings raise the need and provide an opportunity to investigate the association 
between body composition measures, including the novel SMG in a large sample of BC 
patients focusing on adverse treatment-related toxicities. The aim of this study was to 
investigate whether body composition metrics in patients with early BC are independent 
predictors of: (1) chemotherapy toxicity, (2) hospitalizations, and/or (3) dose delays/
reductions.
Methods
Participants
Eligible patients were treated at the North Carolina Cancer Hospital (NCCH) and identified 
through a review of patients in the North Carolina tumor registry in years 2008–2013. To be 
eligible for this study, patients needed to be females older than 21 years receiving 
neoadjuvant or adjuvant chemotherapy treatment for early breast cancer (stage I–III) at 
NCCH. Only doxorubicin-cyclophosphamide (AC)-taxane based chemotherapy regimens for 
early BC were included as most of them had pre-treatment staging CT scan. Patients also 
had to have a CT scan of the abdomen dating no more than 12 weeks prior to chemotherapy 
initiation. All data were extracted from electronic medical records at NCCH. The 
Institutional Review Board at the University of North Carolina (UNC) at Chapel Hill 
approved the study and there was no direct contact with patients.
Toxicity grading
Toxicity grades 3–5 according to National Cancer Institute Common Toxicity Criteria for 
Adverse Events (NCI- CTCAE) Version 4.03(18)) were extracted during and after the 
chemotherapy course through retrospective medical chart review. We hematologic toxicity 
(neutropenia, thrombocytopenia, anemia), febrile neutropenia, and common non-
hematological toxicities –such as neurotoxicity and gastrointestinal (GI) toxicity (stomatitis, 
diarrhea, vomiting). Data on other toxicities -- congestive heart failure (CHF), deep vein 
thrombosis (DVT), pulmonary emboli (PE), and leukemia -- were also gathered from the 
medical record. Dose reductions (any dose reduction by the treating physician), treatment 
delays (any delay based on a toxicity event), and hospitalizations due to chemotherapy 
toxicity were also collected.
CT-based body composition analysis
Abdominal CT images were acquired from the UNC Picture Archiving and Communication 
System (PACS) office. Measuring muscle metrics at L3 level is the most commonly used 
technique utilizing CT scans and validated as highly correlated to total body muscle mass 
(r2= 0.86) (19). CT images were examined using AGFA-Impax (version 6) radiological 
software (Mortsel, Belgium), and transverse sections at the L3 level were extracted for 
external analysis. L3 lumbar segments were processed using the “Automated Body 
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Composition Analyzer using Computed tomography image Segmentation” (ABACS) 
software(20, 21). The software recognizes muscle tissue based on a density threshold 
between −29 and +150 HU, while using a priori information about the L3 muscle shape to 
avoid mislabeling parts of the neighboring organs that have HU values in the [−29 to +150] 
range as muscle tissue. The program provides a highly accurate (22) and unbiased estimation 
of the cross-sectional lean tissue area and skeletal muscle area (SMA) (Figure 1). SMI was 
calculated using the following formula: (skeletal muscle area-cm2)/(patient height-m2). 
Estimated lean body mass (LBM) was calculated using the following formula: [LBM (kg) = 
0.30 × [skeletal muscle at L3 using CT (cm2)] + 6·06](14). Mean skeletal muscle density 
(SMD) was derived by averaging HU of skeletal muscle. To integrate both the skeletal 
muscle quantity (SMI) and the density (SMD), skeletal muscle gauge (SMG) was calculated 
by multiplying SMI x SMD. The actual units for SMG are (cm2 tissue * average HU)/ (m2 
height) and for simplicity we present them as arbitrary units (AU). Subcutaneous adipose 
tissue (SAT) area was calculated from extramuscular tissue with density between −190 and 
−30 HU, and visceral adipose tissue (VAT) from non-subcutaneous tissue with density 
between −150 and −50 HU. An investigator (MW) was trained by a radiologist to obtain the 
images and a radiologist reviewed the images for quality assurance. The imaging results 
were masked from the investigator obtaining toxicity data.
Patient & clinical characteristics
In addition to toxicity data, we also collected age at diagnosis, HR and HER2 subtypes, 
stage at diagnosis, timing of chemotherapy (neoadjuvant/adjuvant), whether a biologic agent 
was used with chemotherapy, the type of taxane chemotherapy, height, and weight. Body 
surface area (BSA) was calculated: . BMI was calculated: 
BMI = weight (kg) / height2 (m2). We defined sarcopenic obesity as a patient with a BMI 
≥30.0 kg/m2 and a SMI≤41 cm2/m2 (12).
Statistical analysis
Relative risks (RR) and 95% Confidence Interval (CI) are reported for associations between 
body composition measures and toxicity outcomes. Both unadjusted and adjusted RR were 
calculated using Poisson regression models with robust variance(23). Receiver operating 
characteristic (ROC) curves were generated, as well as the area under the curve (AUC), to 
evaluate the predictive ability of each body composition measure. Using the Youden index, 
the point which maximizes both the sensitivity and specificity was determined to be the best 
cut-point for SMG. All analyses were conducted using SAS v9.4 statistical software (Cary, 
NC).
Results
Study population
Patient characteristics are summarized in Table S1 (selection process is shown in Figure S1). 
A total of 151 patients were identified who received adjuvant or neoadjuvant, AC-taxane 
chemotherapy (dosing and scheduling in Table S2) and were treated at NCCH. Mean age 
was 49 years (range 23 to 75) and 74% were white. The mean time from CT scan to 
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chemotherapy initiation was 23 days (SD 19). All patients with HER2 positive tumors 
received concomitant anti-HER2 treatment during chemotherapy. No patients had grade 5 
toxicity recorded (death).
Body composition as a predictor of any grade 3–4 toxicity
Fifty patients (33%) developed grade 3–4 toxicity during chemotherapy treatment, and these 
toxicities were associated with poorer body composition. The relationship of toxicity and 
body composition by tertile is presented in Figure 2. Unadjusted relative risks for each body 
composition measure are shown in Table 1. For every 5kg decrease in LBM, the risk of any 
toxicity increased by 36% (RR = 1.36 [1.12, 1.66], p=0.002). For every 5-unit decrease in 
SMI, the risk of any toxicity increased by 27% (RR = 1.27 [1.09, 1.49], p=0.002). For every 
100 AU decrease in SMG, the risk of any toxicity increased by 8% (RR = 1.08 [1.02, 1.15], 
p=0.006). While not statistically significant, the risk of any toxicity also increased for every 
5 unit decrease in SMD (RR = 1.11 [0.98, 1.25], p=0.08). BMI, BSA, SAT/VAT area, and 
SAT/VAT density were not associated with any grade 3–4 toxicity. Significant associations 
observed in the unadjusted analysis remained statistically significant after adjustment for age 
and BSA (Table 2). Similarly, after adjusting for race and the use of g-CSF, SMG 
associations with toxicity risk remained significant.
In Figure S2, receiver operating characteristic (ROC) curves, along with area under the curve 
(AUC) statistics are shown for each measure based on the outcome of ‘any toxicity’. BMI 
and BSA show poor discrimination (AUC~0.5), while other measures demonstrate better 
discrimination, with SMG being the best (AUC=0.65). Using the Youden index, we 
identified an SMG cut-point of 1475. Figure 3 illustrates the proportion of patients above 
and below this cut-point for different toxicities and demonstrates that patients with an SMG 
below the cut-point had more hematological and gastrointestinal grade 3–4 toxicities as well 
as hospitalizations. Patients with low SMG (< 1475 AU) were about twice as likely to 
experience any toxicity compared to patients with high SMG (≥ 1475 AU) (RR = 2.15 [1.36, 
3.40], p=0.001). Although there were only five patients with sarcopenic obesity in our 
sample (of them 4 received g-CSF), all grade 3–4 hematological toxicities (RR=3.02 [1.38–
6.63], p=0.006), dose reductions or delays (RR = 2.65 [1.61–4.39], p<0.001), and 
neutropenia (RR=3.5 [1.57–7.8], p=0.002) were significantly more likely to occur in these 
patients.
We additionally performed a sensitivity analysis of patients that received paclitaxel only 
(n=142) and found that after generating SMG cut point based on this population, SMG 
remained a significant predictor of grade 3–4 toxicity (RR=2.48) as well as grade 3–4 
hematological toxicities (RR=2.26), GI toxicities (RR=12.17), and hospitalizations 
(RR=2.10).
Body composition as a predictor of grade 3–4 hematologic toxicity
Hematological toxicities were reported in 35 patients (23%), including neutropenia, 
thrombocytopenia, and anemia (see Table S1). Low SMG was significantly associated with a 
higher risk of hematological toxicity -- twice as high among the patients with SMG <1475 as 
compared to the patients with SMG ≥1475 (RR = 2.00 [1.08, 3.72], p=0.03). After adjusting 
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for age and BSA, the high risk for hematological toxicities in the low SMG group remained 
statistically significant.
Body composition as a predictor of grade 3–4 gastrointestinal toxicity and neuropathy
Seven patients (5%) had grade 3–4 gastrointestinal (GI) toxicity and eleven (7%) had grade 
3–4 neuropathy (see Tables 1 and 2). In unadjusted analyses, SMG was the only body 
composition measure significantly associated with GI toxicity. For every 100-unit decrease 
in SMG, the risk of GI toxicity increased by 28% (RR = 1.28 [1.08, 1.51], p=0.004). 
However, after adjustment for age and BSA, lower LBM, SMI, SMD, and SMG were 
significantly associated with an increased risk for GI toxicity. In unadjusted analyses, SMG 
was the only body composition measure significantly associated with grade 3–4 neuropathy. 
For every 100-unit decrease in SMG, the risk of neuropathy increased by 15% (RR = 1.15 
[1.00, 1.31], p=0.04). However after adjusting for age and BSA, the association between 
SMG and neuropathy was no longer statistically significant.
Body composition as a predictor of hospitalizations
Thirty patients (20.7%) of 145 patients with full hospitalization records were hospitalized 
for treatment-related toxicity. For every 5-unit decrease in SMD, the risk of hospitalization 
increased by 19% (RR = 1.19 [1.00, 1.43], p=0.05). After adjustment for age and BSA, 
SMD remained a significant predictor and patients with SMG <1475 as compared to the 
patients with SMG ≥1475 had twice the hospitalization risk (RR = 1.91 [1.00, 3.66], 
p=0.05). All other body composition measures were unrelated to hospitalization in both 
unadjusted and adjusted models.
Discussion
This is the first study, to our knowledge, to evaluate the relationship of LBM, SMG and 
other body composition measures with treatment toxicity in a large sample of early breast 
cancer patients receiving the commonly used chemotherapy regimens of an anthracycline 
and taxane. After adjusting for age and BSA, lower LBM was significantly associated with 
having any grade 3–4 toxicity as well as grade 3–4 GI toxicity. SMG, a novel integrated 
measure of body composition, was significantly associated with having any grade 3–4 
toxicity as well as grade 3–4 GI toxicities, hematological toxicities, and hospitalizations. As 
illustrated by the large number of body composition measures analyzed in this study, body 
composition is extremely variable. However, measures that include muscle metrics are 
clearly related to the toxicity, while adipose metrics, (BMI and BSA) are not. In addition, the 
small number of patients with sarcopenic obesity had significantly more dose adjustments 
and hematological toxicities compared to patients who were not both sarcopenic and obese. 
Of note, aging is associated with decreasing muscle mass and lower muscle density, and age 
related changes are more correlated with SMG than either SMI or SMD alone (17).
Our findings are supported by other studies. Prado et al., in a small (n=24) but novel study, 
found that higher toxicity was associated with lower LBM in patients with early breast 
cancer receiving epirubicin containing adjuvant therapy (56.2 vs 41.6 kg, p=0.002). In that 
study, LBM was also an independent and significant predictor of epirubicin 
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pharmacokinetics (PK) and toxicity(15). Tamandl et al. observed that low skeletal muscle 
density was associated with poorer survival in patients with gastric cancer (HR =1.91, 95 % 
CI 1.12–3.28, p=0.019).(24)Others have also found an association of body composition with 
toxicity and survival in early cancer(13, 15, 25).
A unique aspect of our study is the use of a new metric – skeletal muscle gauge (SMG) – 
that takes into account both muscle quantity (SMI) and quality (SMD). Of all the metrics, 
SMG was the single most predictive of toxicity. Based on ROC analyses for any grade 3–4 
toxicity, we determined the best cut-point for SMG to be 1475. Using this cut-point, we 
found that low SMG was associated with grade 3–4 GI toxicity and grade 3–4 hematological 
toxicity and hospitalizations after adjusting age and BSA (Figure 3). Furthermore, after 
adjusting for g-CSF usage and race, this SMG cut-point remained significant. This cut-point 
might be helpful in identifying patients at high risk for toxicity and should be explored in 
future trials. Moreover, we have previously shown that low SMG in an older cancer 
population is correlated with lower physical function and increased frailty,22,23 both of 
which are associated with poorer cancer outcomes and shortened survival.(26)
Our study has some limitations. First, our cohort included only a small sample of older 
patients (>65 years; n=9). Older patients comprise a large portion of the breast cancer 
population and age is associated with decreased muscle mass and muscle density. Second, 
many patients now receive non- anthracycline containing chemotherapy and future work will 
need to explore the role of muscle metrics and body composition for these chemotherapy 
regimens. This may be challenging since many patients treated with non-anthracycline 
regimens present with Stage I or II breast cancer where baseline CT scans are not 
recommended.(27) Third, performance status (PS) was recorded only for 78 patients in our 
sample, all of whom had excellent scores of 0 or 1 (ECOG) and comorbidities were not 
consistently reported in the medical chart. However, PS scores of 0 or 1 are typical of 
patients in clinical trials, as well as those who are treated with more toxic anthracycline-
taxane based chemotherapy regimens. Furthermore, the clinical decision to use 
chemotherapy was made by the physician with patient input, and we assumed that 
comorbidities were taken into account when recommending the treatment plan. Another 
potential limitation is the use of different taxane regimens but a sensitivity analysis of the 
142 patients that received paclitaxel only showed that SMG remained a significant predictor 
of grade 3–4 hematological toxicities, GI toxicities and hospitalizations. The final limitation 
is the use of retrospective data in assessing toxicity outcomes; for this reason we chose to 
collect only grade 3–4 toxicities which are medically meaningful and usually documented in 
the patient chart.(28)
Despite major limitations in its accuracy at predicting treatment efficacy and toxicity, body 
surface area (BSA) has traditionally been used in oncology to dose chemotherapy(29, 30). 
After controlling for BSA, we showed that LBM and SMG were still highly effective 
predictors of grade 3 and 4 toxicities. Based on ROC analyses, we found that LBM and 
SMG were the best predictors of severe chemotherapy toxicity (see Figure S2). BSA dosing 
based only on weight and height ignores whether the weight is related to increased adipose 
tissue or to LBM, which is problematic in light of the low correlation between LBM and 
BSA(31). In patients with increased adiposity and low LBM in our study, standard BSA-
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based dosing was associated with high toxicity rates (see Figure 1 for an example). There is 
growing evidence to support our conclusion that LBM is better at predicting treatment 
toxicity than BSA for both anthracyclines and 5FU(13, 15).
Our results add to the increasing body of research showing that chemotherapy toxicity is 
clearly associated with body composition. Moreover, we have defined the importance of 
body composition in predicting toxicity for patients with early breast cancer, one of the most 
common cancers worldwide, and for chemotherapy regimens that are widely used. Our 
results demonstrate the importance of LBM and body composition in cancer patients 
highlights the need for specific interventions to improve unfavorable body composition and 
to potentially decrease treatment-related toxicity. Several treatments for sarcopenia of 
potential benefit include anamerolin(32), exercise(33, 34), and omega-3 fatty acid dietary 
supplementation(35). The generation of individualized body composition measures from 
readily available CT scans holds great promise in individualizing and improving 
chemotherapy outcomes, and validation of these measures in prospective trials is urgently 
needed. Such trials should compare body composition measures with both toxicity and 
efficacy outcomes and should ideally include PK measures of the chemotherapeutic or 
biologic agents.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF TRANSLATIONAL RELEVANCE
Currently, chemotherapy dosing is commonly based on the body surface area (BSA) 
formula, which accounts for height and weight only but not for other potentially 
important body composition indices. This manuscript presents the largest study to date 
assessing the impact of several body composition measures on chemotherapy toxicity in 
patients with early breast cancer receiving adjuvant chemotherapy. Our results show that 
skeletal muscle gauge (SMG), a new and innovative metric derived from the combination 
of muscle mass (quantity) and radiodensity (quality), is the best predictor of 
chemotherapy adverse outcomes including grade 3–4 chemotherapy toxicities, 
hospitalizations, and other adverse events. ROC curves show SMG is a better predictor of 
chemotherapy toxicity than either lean body mass or BSA. Our results suggest that body 
composition measurements obtained from routine computed tomography (CT) images 
performed for staging might be used to individualize chemotherapy dosing and 
potentially improve its therapeutic index.
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Figure 1. 
Skeletal muscle gauge and toxicity-Both female-BSA 1.70
Left–normal SMG (2535 AU), no toxicity; Right-low SMG (844 AU), had grade 3–4 
toxicity.
Abbreviations: BSA:Body Surface area; HU:Hounsfield units; AU: arbitrary units
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Figure 2. 
Risk of toxicity based on tertiles of body composition measures
Abbreviations: SMG: skeletal muscle gauge, SMI: skeletal Muscle index, SMD: skeletal 
muscle density, LBM: lean body mass, HU: Hounsfield units, AU: arbitrary units ; *p-values 
from unadjusted Jonckheere-Terpstra tests
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Figure 3. 
Risk of toxicity based on skeletal muscle gaugea
ap values from Poisson regression models adjusting for age at diagnosis and BSA
*Grade 3–4 toxicity
Abbreviations: SMG: skeletal muscle gauge; BSA: body surface area
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